Identification of a candidate prognostic gene signature by transcriptome analysis of matched pre- and post-treatment prostatic biopsies from patients with advanced prostate cancer

Table 1 Patient demographics of samples for RNA-Seq following docetaxel chemotherapy plus ADT

Patient	KPS	GSS	T	N	M	iPSA (ng/ml)	nPSA (ng/ml) (% iPSA)	PFS (days)
1	90	9	4	1	1	8.76	0.09 (1.0)	317
2^*	90	7^$	3b	1	0	8.44	1.3 (15.4)	105
3^*	90	8	3b	0	0	25.8	0.19 (0.7)	834
4	90	7	3b	1	1	80.8	0.08 (0.1)	588
5	90	9	3b	0	0	2.85	0.08 (2.8)	N/P
6	90	7	3b	1	1	636	0.1 (0.0)	N/P

All patients exhibited a response to docetaxel plus ADT prior to second TRUSS-guided biopsy as determined by a fall in levels of serum PSA. The mean time to second TRUSS-guided biopsy was 156 ± 37 days. ^*Samples removed from RNA-seq analysis. ^$Tertiary Gleason grade 5. (KPS = Karnofsky Performance Status; GSS = Gleason Sum Score; iPSA = initial PSA value at diagnosis; nPSA = nadir PSA value prior to second TRUSS-guided biopsy; PFS = biochemical progression-free survival; N/P = not yet progressed).

ISSN: 1471-2407